Chaos control in cardiac dynamics: terminating chaotic states with local minima pacing

Current treatments of cardiac arrhythmias like ventricular fibrillation involve the application of a high-energy electric shock, that induces significant electrical currents in the myocardium and therefore involves severe side effects like possible tissue damage and post-traumatic stress. Using nume...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in network physiology Vol. 4; p. 1401661
Main Authors Suth, Daniel, Luther, Stefan, Lilienkamp, Thomas
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.07.2024
Subjects
Online AccessGet full text
ISSN2674-0109
2674-0109
DOI10.3389/fnetp.2024.1401661

Cover

More Information
Summary:Current treatments of cardiac arrhythmias like ventricular fibrillation involve the application of a high-energy electric shock, that induces significant electrical currents in the myocardium and therefore involves severe side effects like possible tissue damage and post-traumatic stress. Using numerical simulations on four different models of 2D excitable media, this study demonstrates that low energy pulses applied shortly after local minima in the mean value of the transmembrane potential provide high success rates. We evaluate the performance of this approach for ten initial conditions of each model, ten spatially different stimuli, and different shock amplitudes. The investigated models of 2D excitable media cover a broad range of dominant frequencies and number of phase singularities, which demonstrates, that our findings are not limited to a specific kind of model or parameterization of it. Thus, we propose a method that incorporates the dynamics of the underlying system, even during pacing, and solely relies on a scalar observable, which is easily measurable in numerical simulations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Richard H. Clayton, The University of Sheffield, United Kingdom
Richard A. Gray, United States Food and Drug Administration, United States
Reviewed by: Simone Scacchi, University of Milan, Italy
Edited by: Alessio Gizzi, Campus Bio-Medico University, Italy
ISSN:2674-0109
2674-0109
DOI:10.3389/fnetp.2024.1401661